Qymune Inc., a biotechnology company developing next-generation T-cell engager therapeutics, today announced that its research collaboration with Daiichi Sankyo (TSE: 4568) has advanced into its second phase ahead of the timeline originally planned for the program. The collaboration, which was announced in February 2026 and being led by scientists at Qymune and the Daiichi Sankyo Research Institute San Diego, is evaluating Qymune's proprietary Q²TCE platform technology for an undisclosed oncology target.

Qymune retains ownership of its platform technology and research intellectual property. Financial terms were not disclosed.

"Reaching the next phase of this collaboration ahead of schedule speaks to the execution of our team and to how quickly the Q²TCE platform can be applied to a new target," said Jaehak Oh, Ph.D., Chief Executive Officer of Qymune. "Continued engagement from a global oncology leader reinforces our conviction that T-cell engagers can be designed safe. We are grateful to the Daiichi Sankyo team for their collaboration and look forward to building on this momentum together."

About Qymune Inc.

Qymune Inc. is a San Francisco-based biotechnology company advancing next-generation T-cell engager therapeutics through its proprietary Q²TCE platform. The company's lead program, QYM1, is a CD19-targeting T-cell engager in development for autoimmune diseases and B-cell lymphoma. Qymune is backed by institutional investors and is headquartered in San Francisco, California.

About Q²TCE Technology

Qymune's Q²TCE platform represents a first-in-class approach to T-cell engagement with a proprietary target rather than the receptor used by conventional T-cell engagers. This differentiated mechanism may enable a superior therapeutic index while significantly reducing cytokine release – a key driver of cytokine release syndrome (CRS) that has limited the clinical utility of many T-cell engager programs. The platform's proprietary antibody panel offers tunable binding affinities, enabling rapid pairing with diverse antibody targets across oncology and autoimmune disease applications.

Forward-Looking Statements

This announcement contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those anticipated. Qymune undertakes no obligation to update these statements.